Arkolith/Insider Trading/KIN/Form 4

Wee Wendy

Chief Financial OfficerKindred Biosciences, Inc. (KIN) · full profile →Form 4 · filed Aug 30, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
9
1 non-derivative · 8 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 27, 2021Disposed to issuer(D)79K$9.25$727K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 27, 2021Disposed to issuer(D)33K$2.29$74K0
Aug 27, 2021Disposed to issuer(D)75K$2.85$214K0
Aug 27, 2021Disposed to issuer(D)84K$4.81$402K0
Aug 27, 2021Disposed to issuer(D)10K$6.00$60K0
Aug 27, 2021Disposed to issuer(D)100K—$00
Aug 27, 2021Disposed to issuer(D)75K$0.50$38K0
Aug 27, 2021Disposed to issuer(D)50K—$00
Aug 27, 2021Disposed to issuer(D)50K$2.15$108K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001250853-21-000091) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML